Roche’s Fenebrutinib Confirms Potential as First BTK Inhibitor for MS in Third Positive Phase III Trial (FENhance 1)

Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary…








